Trial Profile

Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms IVORY Study

Most Recent Events

19 Oct 2020 Status changed from active, no longer recruiting to completed.
01 Jun 2020 Primary endpoint (complete response rate) has not been met.
01 Jun 2020 Results published in the Annals of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com